Global Acute on Chronic Liver Failure Market is Segmented By Disease Type (Type-A ACLF, Type B ACLF, Type C ACLF), By Therapy Type (Liver Transplantation, Supportive Care, Medications, Others), By End User (Hospitals, Ambulatory Surgical Centers, Others), and By Region (North America, Europe, South America, Asia Pacific, Middle East, and Africa) – Share, Size, Outlook, and Opportunity Analysis, 2024-2031
Market Overview
Global Acute on Chronic Liver Failure market reached US$ YY million in 2023 and is expected to reach US$ YY million by 2031, growing at a CAGR of YY % during the forecast period 2024-2031.
Acute-on-Chronic Liver Failure (ACLF) is a critical medical condition characterised by the sudden deterioration of liver function in individuals with underlying chronic liver disease. This complex syndrome is marked by a rapid onset of severe liver dysfunction and is often associated with multiple organ failures. ACLF requires immediate medical attention and intervention, posing a high mortality risk. Effective management strategies and early detection are crucial in improving the prognosis for patients with ACLF, making it a significant focus in gastroenterology and hepatology.
Market Summary
| Metrics | Details |
| CAGR | YY% |
| Market Size Available for Years | 2022-2031 |
| Estimation Forecast Period | 2024-2031 |
| Revenue Units | Value (US$ Mn) |
| Segments Covered | Disease Type, Therapy Type, End User |
| Regions Covered | North America, Europe, Asia-Pacific, South America, and Middle East & Africa |
| Largest Region | North America |
| Fastest Growing Region | Asia-Pacific |
| Report Insights Covered | Competitive Landscape Analysis, Company Profile Analysis, Market Size, Share, Growth, Demand, Recent Developments, Mergers and Acquisitions, New Product Launches, Growth Strategies, Revenue Analysis, Porter’s Analysis, Pricing Analysis, Regulatory Analysis, Supply-Chain Analysis and Other key Insights. |
For more details on this report – Request for Sample
Market Dynamics
Rise in the prevalence of chronic liver diseases
The rise in chronic liver diseases like cirrhosis and hepatitis is a significant factor contributing to the development of acute on chronic liver failure (ACLF). For instance, Liver disease accounts for two million deaths annually and is responsible for 4% of all deaths (1 out of every 25 deaths worldwide); approximately two-thirds of all liver-related deaths occur in men. Within this estimate, liver cancer accounts for 600,000 to 900,000 deaths per year.
Currently, liver disease is the eleventh-leading cause of death, but liver deaths may be underestimated. Deaths are largely attributable to complications of cirrhosis and hepatocellular carcinoma, with acute hepatitis accounting for a smaller proportion of deaths.
Furthermore, the global acute on chronic liver failure market is also driven by various factors like high-risk patient populations, government initiatives to promote awareness and others that help the market to grow during the forecast period.
Complications associated with the disease
The complications associated with acute or chronic liver failure (ACLF) include multisystem organ failure and poor prognosis in hospitalized patients with cirrhosis. ACLF is characterized by rapid clinical deterioration and is associated with high short-term morbidity, mortality, and healthcare resource utilization. Also, complications like infections, kidney problems and other issues will also occur after liver transplantation.
Market Segmentation
The global acute on chronic liver failure market is segmented based on disease type, therapy type, end user and region.
The liver transplantation from the therapy type segment accounted for approximately 47.1% of the acute on chronic liver failure market share
The liver transplantation from the therapy type segment accounted for approximately 47.1% Acute-on-chronic liver failure (ACLF) is a syndrome that develops in 30% of the patients hospitalized due to cirrhosis. About 30% of patients with ACLF will die within 28 days of hospital admission. Although liver transplantation has been shown to be the most effective treatment for patients with ACLF grade 2-3 to date, with more than an 80% survival rate after 1 year of receiving a liver transplant access to liver transplantation in some European countries is limited in treating patients with cirrhosis. In collaboration with the European Liver and Intestine Transplantation Society (ELITA) and the International Liver Transplantation Society (ILTS), EF Clif launched the CHANCE study, its largest prospective non-interventional observational global study to assess the survival rate of patients with cirrhosis who receive a liver transplant.
Market Geographical Share
North America is Expected to Dominate the Global Market
North America is estimated to hold about 38.4% of the total market share throughout the forecast period owing to the factors increasing awareness, and rising incidence of liver failure in the region. Additionally, due to the growing ageing population and increasing awareness regarding the available treatment options for the population also help the region to have the highest market share.
For instance, in May 2023, Seal Rock Therapeutics, Inc., a clinical-stage company developing first-in-class and best-in-class kinase inhibitors, stated that it has entered into an out-licensing agreement with GENFIT for the development of an injectable formulation of SRT-015 for acute liver disease, including Acute-on-Chronic Liver Failure (ACLF).
Covid 19 Impact Analysis
COVID-19 significantly impacts patients with compensated chronic liver disease (CLD), increasing the risk of disease progression and acute-on-chronic liver failure (ACLF). CLD patients have a higher risk of severe or critical COVID-19 and higher mortality, while ACLF is observed in some patients with pre-existing compensated CLD who had severe COVID-19. Furthermore, patients with CLD are more likely to experience severe or critical COVID-19 and higher mortality.
Key Developments
- In June 2023, Ipsen and GENFIT stated that positive topline data from the pivotal ELATIVE Phase III trial. In the trial the efficacy and safety of elafibranor, an investigational dual α,δ PPAR agonist, is being assessed for the treatment of patients with the rare cholestatic liver disease, primary biliary cholangitis (PBC), who have an inadequate response or intolerance to the current standard of care therapy, ursodeoxycholic acid (UDCA).
Market Competitive Landscape
The major global players in the market include Grifols Therapeutics, Genefit (Versantis), Martin Pharmaceuticals, Fresenius SE & Co. KGaA, Cellaion, Yaqrit Discovery Ltd, GNI Group Ltd among others.
Why Purchase the Report?
- To visualize the global acute on chronic liver failure market segmentation based on disease type, therapy type, end user and region as well as understand key commercial assets and players.
- Identify commercial opportunities by analysing trends and co-development.
- Excel data sheet with numerous data points of acute on chronic liver failure market-level with all segments.
- PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
- Product mapping available as excel consisting of key products of all the major players.
The global acute on chronic liver failure market report would provide approximately 64 tables, 61 figures and 186 pages.
Target Audience 2024
- Manufacturers/ Buyers
- Industry Investors/Investment Bankers
- Research Professionals
- Emerging Companies
